Effects of Co-Trimoxazole on Microbial Translocation in HIV-1-Infected Patients Initiating Antiretroviral Therapy

AIDS Research and Human Retroviruses

Volumn 31, Issue 8, 2015, Pages 830-836

  Vesterbacka, Jan ^a   Barqasho, Babilonia ^a   Häggblom, Amanda ^a,b   Nowak, Piotr ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Public Dental Service   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; BIOLOGICAL MARKER; CD14 ANTIGEN; COTRIMOXAZOLE; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; FATTY ACID BINDING PROTEIN; LAMIVUDINE; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE BINDING PROTEIN; LOPINAVIR; RALTEGRAVIR; TENOFOVIR; VIRUS RNA; ZIDOVUDINE; ACUTE PHASE PROTEIN; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; CARRIER PROTEIN; LIPOPOLYSACCHARIDE-BINDING PROTEIN; MEMBRANE PROTEIN;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE DEFICIENCY; INTESTINE FLORA; LIMULUS LYSATE TEST; MALE; MICROBIAL TRANSLOCATION; MICROBIOLOGICAL PHENOMENA AND FUNCTIONS; PNEUMOCYSTIS JIROVECI INFECTION; PNEUMOCYSTOSIS; PRIORITY JOURNAL; ANIMAL; ANTIBIOTIC PROPHYLAXIS; BACTERIAL TRANSLOCATION; BLOOD; COMPLICATION; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIROLOGY;

ACUTE-PHASE PROTEINS; ADULT; AGED; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-RETROVIRAL AGENTS; ANTIBIOTIC PROPHYLAXIS; ANTIGENS, CD14; BACTERIAL TRANSLOCATION; BIOMARKERS; CARRIER PROTEINS; FATTY ACID-BINDING PROTEINS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LIPOPOLYSACCHARIDES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION;

EID: 84938852381     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2014.0366     Document Type: Article

References (32)

1. Guadalupe M, Reay E, Sankaran S, et al.: Severe CD4+ Tcell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003;77(21):11708-11717.
2. Kotler DP, Reka S, Borcich A, and Cronin WJ: Detection, localization, and quantitation of HIV-associated antigens in intestinal biopsies from patients with HIV. Am J Pathol 1991;139(4):823-830.
3. Brenchley JM, Paiardini M, Knox KS, et al.: Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 2008;112(7):2826-2835.
4. Brenchley JM, Price DA, Schacker TW, et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12(12):1365-1371.
5. Lakatos PL, Kiss LS, Palatka K, et al.: Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease. Inflamm Bowel Dis 2011;17(3):767-777.
6. Assimakopoulos SF, Papageorgiou I, and Charonis A: Enterocytes' tight junctions: From molecules to diseases. World J Gastrointest Pathophysiol 2011;2(6):123-137.
7. Opal SM, Scannon PJ, Vincent JL, et al.: Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999;180(5):1584-1589.
8. Troseid M, Nowak P, Nystrom J, et al.: Elevated plasma levels of lipopolysaccharide and high mobility group box-1 protein are associated with high viral load in HIV-1 infection: Reduction by 2-year antiretroviral therapy. AIDS 2010;24(11):1733-1737.
9. Merlini E, Bai F, Bellistri GM, et al.: Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy. PLoS One 2011;6(4):e18580.
10. Vesterbacka J, Nowak P, Barqasho B, et al.: Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy. PLoS One 2013; 8(1):e55038.
11. Svard J, Sonnerborg A, Vondracek M, et al.: On the usefulness of circulating bacterial 16S rDNA as a marker of microbial translocation in HIV-1-infected patients. J Acquir Immune Defic Syndr 2014;66(4):e87-89.
12. Nowak P, Abdurahman S, Lindkvist A, et al.: Impact of HMGB1/TLR ligand complexes on HIV-1 replication: Possible role for flagellin during HIV-1 infection. Int J Microbiol 2012;2012:263836.
13. Sandler NG and Douek DC: Microbial translocation in HIV infection: Causes, consequences and treatment opportunities. Nat Rev Microbiol 2012;10(9):655-666.
14. Lichtfuss GF, Hoy J, Rajasuriar R, et al.: Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. Biomark Med 2011;5(2):171-186.
15. Grube BJ, Cochane CG, Ye RD, et al.: Lipopolysaccharide binding protein expression in primary human hepatocytes and HepG2 hepatoma cells. J Biol Chem 1994;269(11): 8477-8482.
16. Abdurahman S, Barqasho B, Nowak P, et al.: Pattern of microbial translocation in patients living with HIV-1 from Vietnam, Ethiopia and Sweden. J Int AIDS Soc 2014; 17:18841.
17. Pelsers MM, Hermens WT, and Glatz JF: Fatty acidbinding proteins as plasma markers of tissue injury. Clin Chim Acta 2005;352(1-2):15-35.
18. Jakobsson HE, Jernberg C, Andersson AF, et al.: Shortterm antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One 2010; 5(3):e9836.
19. Vrieze A, Out C, Fuentes S, et al.: Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J Hepatol 2014;60:824-831.
20. Kalambokis GN and Tsianos EV: Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis. Hepatology 2012;55(2):655-656.
21. Cassol E, Malfeld S, Mahasha P, et al.: Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. J Infect Dis 2010;202(5):723-733.
22. Vujkovic-Cvijin I, Dunham RM, Iwai S, et al.: Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med 2013;5(193):193ra191.
23. Nowak P BB, Avershina E, Noyan K, et al.: Decreased Diversity of Gut Microbiota Is Associated with Immune Status during HIV-1 Infection. Abstract Conference on Retroviruses and Opportunistic Infections (CROI) 2014. 2014.
24. Dethlefsen L and Relman DA: Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci USA 2011;108(Suppl 1):4554-4561.
25. Ipp H, Zemlin AE, Glashoff RH, et al.: Serum adenosine deaminase and total immunoglobulin G correlate with markers of immune activation and inversely with CD4 counts in asymptomatic, treatment-naive HIV infection. J Clin Immunol 2013;33(3):605-612.
26. Marchetti G, Merlini E, Sinigaglia E, et al.: Immune reconstitution in HIV+ subjects on lopinavir/ritonavir-based HAART according to the severity of pre-therapy CD4 + . Curr HIV Res 2012;10(7):597-605.
27. Di Mascio M, Srinivasula S, Bhattacharjee A, et al.: Antiretroviral tissue kinetics: In vivo imaging using positron emission tomography. Antimicrob Agents Chemother 2009;53(10):4086-4095.
28. Goovaerts O, Jennes W, Massinga-Loembe M, et al.: LPSbinding protein and IL-6 mark paradoxical tuberculosis immune reconstitution inflammatory syndrome in HIV patients. PLoS One 2013;8(11):e81856.
29. Wallet MA, Rodriguez CA, Yin L, et al.: Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. AIDS 2010;24(9):1281-1290.
30. Chevalier MF, Petitjean G, Dunyach-Remy C, et al.: The Th17/Treg ratio, IL-1RA and sCD14 levels in primary HIV infection predict the T-cell activation set point in the absence of systemic microbial translocation. PLoS Pathog 2013;9(6):e1003453.
31. Pallikkuth S, Fischl MA, and Pahwa S: Combination antiretroviral therapy with raltegravir leads to rapid immunologic reconstitution in treatment-naive patients with chronic HIV infection. J Infect Dis 2013;208(10):1613-1623.
32. Church JA, Fitzgerald F, Walker AS, et al.: The expanding role of co-trimoxazole in developing countries. Lancet Infect Dis 2015;15(3):327-339.